Old version
Old version
Підтверджена електронна адреса в meduniv.lviv.ua - Домашня сторінка
НазваПосиланняРік
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
P O'Connor, M Filippi, B Arnason, G Comi, S Cook, D Goodin, HP Hartung, ...
The Lancet Neurology 8 (10), 889-897, 2009
4202009
Placebo-controlled trial of oral laquinimod for multiple sclerosis
G Comi, D Jeffery, L Kappos, X Montalban, A Boyko, MA Rocca, M Filippi
New England Journal of Medicine 366 (11), 1000-1009, 2012
3352012
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
R Gold, G Giovannoni, K Selmaj, E Havrdova, X Montalban, EW Radue, ...
The Lancet 381 (9884), 2167-2175, 2013
2612013
Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis
O Khan, P Rieckmann, A Boyko, K Selmaj, R Zivadinov, ...
Annals of neurology 73 (6), 705-713, 2013
1822013
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
F Barkhof, HE Hulst, J Drulović, BMJ Uitdehaag, K Matsuda, R Landin
Neurology 74 (13), 1033-1040, 2010
1102010
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
M Filippi, MA Rocca, E Pagani, N De Stefano, D Jeffery, L Kappos, ...
J Neurol Neurosurg Psychiatry 85 (8), 851-858, 2014
942014
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
G Giovannoni, R Gold, K Selmaj, E Havrdova, X Montalban, EW Radue, ...
The Lancet Neurology 13 (5), 472-481, 2014
852014
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ...
Neurology 89 (11), 1117-1126, 2017
692017
Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy
E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ...
Neurology 89 (11), 1107-1116, 2017
582017
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
DH Miller, RJ Fox, JT Phillips, M Hutchinson, E Havrdova, M Kita, ...
Neurology 84 (11), 1145-1152, 2015
392015
Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
C Sampaio, J Bronzova, RA Hauser, AE Lang, O Rascol, SV van de Witte, ...
Movement disorders 26 (8), 1464-1476, 2011
352011
The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study
L Kappos, G Comi, C Confavreux, MS Freedman, AE Miller, TP Olsson, ...
Mult Scler 18 (Suppl 4), 50, 2012
302012
Identification of a 48 kDa form of unconventional myosin 1c in blood serum of patients with autoimmune diseases
S Myronovkij, N Negrych, T Nehrych, MJ Redowicz, S Souchelnytskyi, ...
Biochemistry and biophysics reports 5, 175-179, 2016
222016
How does fingolimod (Gilenya®) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?
F Fazekas, O Bajenaru, T Berger, T Hojs Fabjan, A Horvat Ledinek, ...
Frontiers in neurology 4, 10, 2013
222013
Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis
G Giovannoni, R Gold, K Selmaj, E Havrdova, X Montalban, EW Radue, ...
28th Congress of the European Committee for Treatment and Research in …, 2012
172012
Від вірогідної діагностики до ефективної терапії розсіяного склерозу
ТІ Негрич, БВ Сорокін, СК Євтушенко
Міжнародний неврологічний журнал 3 (49), 152-158, 2012
172012
Рассеянный склероз: актуальность проблемы в Украине, современные аспекты иммунопатогенеза, клиники, диагностики и лечения. Украинский междисциплинарный консенсус
НП Волошина, НН Грицай, ИН Дыкан, СК Евтушенко, ТА Кобысь, ...
Новости медицины и фармации 215, 20-4, 2007
162007
Рассеянный склероз в Украине: распространенность, течение, прогноз, лечение, фармакоэкономика
ПВ Волошин, НП Волошина, ВИ Тайцлин, АГ Лещенко, ...
Український вісник психоневрології, 6-21, 2007
152007
Natalizumab improves ambulation in relapsing− remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
N Voloshyna, E Havrdova, M Hutchinson, T Nehrych, X You, S Belachew, ...
European journal of neurology 22 (3), 570-577, 2015
132015
Доказова база методів діагностики та лікування розсіяного склерозу
ТІ Негрич, СК Євтушенко, БВ Сорокін, МА Москаленко
Міжнародний неврологічний журнал, 215-220, 2012
122012
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20